|Bid||183.00 x 1200|
|Ask||186.39 x 900|
|Day's range||182.59 - 186.76|
|52-week range||182.03 - 285.61|
|Beta (5Y monthly)||1.35|
|PE ratio (TTM)||32.07|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
RESEARCH TRIANGLE PARK, N.C., September 28, 2022--IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation.
RESEARCH TRIANGLE PARK, N.C., September 07, 2022--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced new evidence that decentralized clinical trials (DCT) deliver measurable benefits for patients, sites and sponsors.
RESEARCH TRIANGLE PARK, N.C., September 02, 2022--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Baird 2022 Global Healthcare Conference in New York City on Wednesday, September 14, 2022 at 2:35 p.m. ET.